Has Erika Hamilton, MD received payments from drug or device companies?

Yes. Drug and device makers reported $45,350,019 in general payments to Erika Hamilton, MD across 6,793 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Erika Hamilton, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Erika Hamilton, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Erika Hamilton, MD

Hematology & Oncology · Nashville, TNNPI 1902007107

Payments from drug & device makers

$45,350,019in general payments, 2019–2025

Across 6,793 payments — averaging $6675.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$9M
Pfizer$6.6M
Seagen Inc.$5.2M
Genentech, Inc.$3.7M
Novartis$2.4M
Daiichi Sankyo Inc.$2M
plus $16.4M from 54 others

$158,845in research payments, 2019–2025

Across 97 payments — averaging $1637.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Macrogenics, Inc.$65K
Pfizer$47K
F. Hoffmann-la Roche AG$18K
Eli Lilly$14K
Novartis$10K
Regeneron$4K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	275	$9,001,763
Pfizer	588	$6,583,569
Seagen Inc.	753	$5,211,041
Genentech, Inc.	771	$3,749,556
Novartis	51	$2,400,578
Daiichi Sankyo Inc.	463	$1,996,390
Tesaro, Inc.	147	$1,863,021
GSK	372	$1,706,560
Clovis Oncology, Inc.	135	$1,432,400
Regeneron	195	$1,424,976
Astrazeneca UK Limited	61	$1,248,685
Boehringer Ingelheim International GmbH	143	$1,054,289
Eli Lilly	73	$1,024,902
Deciphera Pharmaceuticals Inc.	811	$794,819
AbbVie	172	$728,655
Taiho Oncology, Inc.	127	$620,066
Karyopharm Therapeutics Inc.	127	$506,723
Roche Products Limited	57	$417,939
Tolmar, Inc.	144	$323,435
Beigene, Ltd.	107	$301,290
ADC Therapeutics America, Inc.	48	$287,483
Amgen	18	$274,763
Macrogenics, Inc.	84	$246,858
Exelixis Inc.	130	$220,788
Merck	27	$196,867
Jazz Pharmaceuticals Inc.	21	$185,990
F. Hoffmann-la Roche AG	68	$178,246
E.r. Squibb & Sons, L.L.C.	34	$177,818
Day One Biopharmaceuticals	50	$167,483
Hoffmann-la Roche Limited	42	$147,220
Gilead(2 entities)	100	$129,458
Radius Health, Inc.	37	$91,620
Stemline Therapeutics Inc.	41	$89,847
Immunogen, Inc.	27	$88,428
Beigene USA, Inc.	41	$85,592
Biontech SE	43	$78,972
Genmab U.S., Inc.	15	$46,627
Daiichi Sankyo Company LTD	8	$46,438
Incyte Corporation	86	$42,400
Acerta Pharma LLC	2	$40,596
EMD Serono, Inc.	21	$29,685
Immunomedics, Inc.	10	$23,280
Takeda Pharmaceuticals U.S.A., Inc.	14	$18,043
Verastem, Inc.	9	$14,335
Boehringer Ingelheim Pharma GmbH & Co.kg	97	$13,133
G1 Therapeutics, Inc.	16	$12,404
Myriad Genetic Laboratories, Inc.	2	$8,000
Lilly USA, LLC	10	$7,770
Astrazeneca AB	2	$4,147
Janssen Research & Development, LLC	1	$2,600
Regeneron Healthcare Solutions, Inc.	15	$394
Genentech USA, Inc.	13	$368
Eisai Inc.	14	$290
Johnson & Johnson	8	$139
Array Biopharma Inc	6	$111
Bayer	6	$100
Sanofi	4	$83
Tersera Therapeutics LLC	4	$77
Bristol Myers Squibb	3	$67
Tempus AI, Inc	3	$67

How this compares

$45,350,019 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$1,031,539

Medicare patients

198

Services billed

34,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

Ian FlinnNashville$41.2M
Johanna BendellNashville$28.5M
Jesus BerdejaNashville$22.2M
Meredith McKeanNashville$16M
Krish PatelNashville$14.2M
Denise YardleyNashville$13.2M
Todd BauerNashville$10.9M
Wade IamsNashville$8.9M
Benjamin GarmezyNashville$8.4M
Brian RiniNashville$8.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →